146 related articles for article (PubMed ID: 24199708)
1. Homeostatic defects in B cells deficient in the E3 ubiquitin ligase ARF-BP1 are restored by enhanced expression of MYC.
Qi CF; Zhang R; Sun J; Li Z; Shin DM; Wang H; Kovalchuk AL; Sakai T; Xiong H; Kon N; Gu W; Morse HC
Leuk Res; 2013 Dec; 37(12):1680-9. PubMed ID: 24199708
[TBL] [Abstract][Full Text] [Related]
2. Characterization of ARF-BP1/HUWE1 interactions with CTCF, MYC, ARF and p53 in MYC-driven B cell neoplasms.
Qi CF; Kim YS; Xiang S; Abdullaev Z; Torrey TA; Janz S; Kovalchuk AL; Sun J; Chen D; Cho WC; Gu W; Morse Iii HC
Int J Mol Sci; 2012; 13(5):6204-6219. PubMed ID: 22754359
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of arf-bp1 induces p53 activation and diabetic phenotypes in mice.
Kon N; Zhong J; Qiang L; Accili D; Gu W
J Biol Chem; 2012 Feb; 287(7):5102-11. PubMed ID: 22187431
[TBL] [Abstract][Full Text] [Related]
4. The E3 ubiquitin ligase Mule acts through the ATM-p53 axis to maintain B lymphocyte homeostasis.
Hao Z; Duncan GS; Su YW; Li WY; Silvester J; Hong C; You H; Brenner D; Gorrini C; Haight J; Wakeham A; You-Ten A; McCracken S; Elia A; Li Q; Detmar J; Jurisicova A; Hobeika E; Reth M; Sheng Y; Lang PA; Ohashi PS; Zhong Q; Wang X; Mak TW
J Exp Med; 2012 Jan; 209(1):173-86. PubMed ID: 22213803
[TBL] [Abstract][Full Text] [Related]
5. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor.
Chen D; Kon N; Li M; Zhang W; Qin J; Gu W
Cell; 2005 Jul; 121(7):1071-83. PubMed ID: 15989956
[TBL] [Abstract][Full Text] [Related]
6. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
Eischen CM; Weber JD; Roussel MF; Sherr CJ; Cleveland JL
Genes Dev; 1999 Oct; 13(20):2658-69. PubMed ID: 10541552
[TBL] [Abstract][Full Text] [Related]
7. ARF-BP1 as a potential therapeutic target.
Chen D; Brooks CL; Gu W
Br J Cancer; 2006 Jun; 94(11):1555-8. PubMed ID: 16641901
[TBL] [Abstract][Full Text] [Related]
8. Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development.
Eischen CM; Alt JR; Wang P
Oncogene; 2004 Nov; 23(55):8931-40. PubMed ID: 15467748
[TBL] [Abstract][Full Text] [Related]
9. FoxO transcription factors suppress Myc-driven lymphomagenesis via direct activation of Arf.
Bouchard C; Lee S; Paulus-Hock V; Loddenkemper C; Eilers M; Schmitt CA
Genes Dev; 2007 Nov; 21(21):2775-87. PubMed ID: 17974917
[TBL] [Abstract][Full Text] [Related]
10. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
[TBL] [Abstract][Full Text] [Related]
11. Gliomagenesis arising from Pten- and Ink4a/Arf-deficient neural progenitor cells is mediated by the p53-Fbxw7/Cdc4 pathway, which controls c-Myc.
Kim HS; Woolard K; Lai C; Bauer PO; Maric D; Song H; Li A; Kotliarova S; Zhang W; Fine HA
Cancer Res; 2012 Nov; 72(22):6065-75. PubMed ID: 22986743
[TBL] [Abstract][Full Text] [Related]
12. USP4 inhibits p53 through deubiquitinating and stabilizing ARF-BP1.
Zhang X; Berger FG; Yang J; Lu X
EMBO J; 2011 Jun; 30(11):2177-89. PubMed ID: 21522127
[TBL] [Abstract][Full Text] [Related]
13. Cytoplasmic CUL9/PARC ubiquitin ligase is a tumor suppressor and promotes p53-dependent apoptosis.
Pei XH; Bai F; Li Z; Smith MD; Whitewolf G; Jin R; Xiong Y
Cancer Res; 2011 Apr; 71(8):2969-77. PubMed ID: 21487039
[TBL] [Abstract][Full Text] [Related]
14. E3 ligases Arf-bp1 and Pam mediate lithium-stimulated degradation of the circadian heme receptor Rev-erb alpha.
Yin L; Joshi S; Wu N; Tong X; Lazar MA
Proc Natl Acad Sci U S A; 2010 Jun; 107(25):11614-9. PubMed ID: 20534529
[TBL] [Abstract][Full Text] [Related]
15. MIF loss impairs Myc-induced lymphomagenesis.
Talos F; Mena P; Fingerle-Rowson G; Moll U; Petrenko O
Cell Death Differ; 2005 Oct; 12(10):1319-28. PubMed ID: 15947793
[TBL] [Abstract][Full Text] [Related]
16. Tumor cell-specific inhibition of MYC function using small molecule inhibitors of the HUWE1 ubiquitin ligase.
Peter S; Bultinck J; Myant K; Jaenicke LA; Walz S; Müller J; Gmachl M; Treu M; Boehmelt G; Ade CP; Schmitz W; Wiegering A; Otto C; Popov N; Sansom O; Kraut N; Eilers M
EMBO Mol Med; 2014 Dec; 6(12):1525-41. PubMed ID: 25253726
[TBL] [Abstract][Full Text] [Related]
17. Small mitochondrial Arf (smArf) protein corrects p53-independent developmental defects of
van Oosterwijk JG; Li C; Yang X; Opferman JT; Sherr CJ
Proc Natl Acad Sci U S A; 2017 Jul; 114(28):7420-7425. PubMed ID: 28652370
[TBL] [Abstract][Full Text] [Related]
18. Role of Pirh2 in mediating the regulation of p53 and c-Myc.
Hakem A; Bohgaki M; Lemmers B; Tai E; Salmena L; Matysiak-Zablocki E; Jung YS; Karaskova J; Kaustov L; Duan S; Madore J; Boutros P; Sheng Y; Chesi M; Bergsagel PL; Perez-Ordonez B; Mes-Masson AM; Penn L; Squire J; Chen X; Jurisica I; Arrowsmith C; Sanchez O; Benchimol S; Hakem R
PLoS Genet; 2011 Nov; 7(11):e1002360. PubMed ID: 22125490
[TBL] [Abstract][Full Text] [Related]
19. MYC-driven malignant transformation of mature murine B cells requires inhibition of both intrinsic apoptosis and p53 activity.
Högstrand K; Grandien A
Eur J Immunol; 2019 Mar; 49(3):375-385. PubMed ID: 30281155
[TBL] [Abstract][Full Text] [Related]
20. The tumor suppressor p53 guides GluA1 homeostasis through Nedd4-2 during chronic elevation of neuronal activity.
Jewett KA; Zhu J; Tsai NP
J Neurochem; 2015 Oct; 135(2):226-33. PubMed ID: 26250624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
